Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Overview
Product name
FCP1 peptide (2-11)
Protein description
Synthetic peptide: EVPAAGRVPA-C, corresponding to amino acids 2-11 of Human FCP1This peptide was used as an immunogen for ab5270 - FCP1 antibody.
Properties
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Concentration
Concentration information loading...
Sequence
EVPAAGRVPA -C
Research areas
Epigenetics and Nuclear Signaling >> Transcription >> RNA polymerase
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription >> Other
Epigenetics and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription >> Polymerase
Signal Transduction >> Protein Phosphorylation >> Ser / Thr Phosphatases
Applications
Application notes
This peptide can be used with studies using ab5270.
Protein info
Function
Processively dephosphorylates 'Ser-2' and 'Ser-5' of the heptad repeats YSPTSPS in the C-terminal domain of the largest RNA polymerase II subunit. This promotes the activity of RNA polymerase II.
Tissue specificity
Ubiquitously expressed. Isoform 3 is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and placenta.
Involvement in disease
Defects in CTDP1 are a cause of congenital cataracts facial dysmorphism and neuropathy syndrome (CCFDN) [MIM:604168]. CCFDN is an autosomal recessive developmental disorder that occurs in an endogamous group of Vlax Roma (Gypsies). The syndrome is characterized by a complex clinical phenotype with seemingly unrelated features involving multiple organs and systems. Developmental abnormalities include congenital cataracts and microcorneae, hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, facial dysmorphism and hypogonadism. Central nervous system involvement, with cerebral and spinal cord atrophy, may be the result of disrupted development with superimposed degenerative changes. Affected individuals are prone to severe rhabdomyolysis after viral infections and to serious complications related to general anesthesia (such as pulmonary edema and epileptic seizures).
Sequence similarities
Contains 1 BRCT domain.
Contains 1 FCP1 homology domain.
Post-translational
modifications
Phosphorylated. In the presence of TFIIF, the phosphorylated form has an increased CTD phosphatase activity. The phosphorylation is required for the physical interaction with GTF2F1.
Cellular localization
Nucleus.
Target information above from: UniProt accessionQ9Y5B0
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
References for FCP1 peptide (2-11) (ab23088)
ab23088 has not yet been referenced specifically in any publications.
Publishing research using ab23088? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"